Staff Directory

Prof David Finkelstein

Since graduating with a PhD in Physiology (1991), I have worked to translate knowledge from fundamental science projects to provide clinical applications. Initially my research interests were centered on the physiology of control of movement, age related neurodegeneration and regeneration. I have subsequently used this basic science knowledge and applied it into developing novel therapeutic avenues for the treatment of Parkinson’s disease and parkinsonism. I have authored more than 110 refereed journal reports, plus reviews and book chapters. Of my 110 journal articles, I have been cited over 3,000 times since 2000 (Scopus), with 27 publications with more than 50 citations. Since 2009 I have published 54 publications, and on 21 of these I was first, last or corresponding author.

I am a current board member (2014-) of Parkinson’s Victoria, an organization that raises awareness and funds for services and research that improves the quality of life for people living with Parkinson’s in Victoria, Australia (http://www.parkinsonsvic.org.au/ ). I am a Chair of the World Parkinson’s Day committee (2013-).

Based on my knowledge and expertise, I was invited to be scientific consultant for two local biotech companies, Prana Biotechnology Ltd (2006-ongoing) and Procypria Biotechnology Ltd (2009-2012), as well as international companies, Commonwealth Serum laboratories (2009-2012) and the Collaborative Medicinal Development LLC, USA (2013-present). The aim of consulting with these companies is to work in partnership to develop new compounds that could potentially slow the progression of neurodegenerative diseases. My skills lie in the pre-clinical testing of new compounds in animal models of disease. As head of the preclinical Parkinson's disease development team at Prana Biotechnology, I have been an integral component in progressing specific lead compounds to preclinical toxicology screening (PBT434). The translational work that I commenced is currently progressing along the drug regulatory pathways. My collaboration with these biotechnology companies has increased the likelihood of a clinically relevant compound being available for the treatment of Parkinson’s disease.

I have been involved in the supervision and mentoring of 12 graduate students, 2 of which have won Faculty of Medicine, Dentistry and Health Sciences prizes. 4 have been awarded NHMRC Early Career Fellowships.

I am an academic editor for PLOS One (since 2009) and Journal of Alzheimer’s Disease (2015). I am an ad hoc reviewer of ~50 articles per year. I gave reviewed grants for the NHMRC, Medical Research Council (New Zealand) Alzheimer’s Association and Parkinson’s UK. I have acted as an external reviewer for The Eskitis Institute for Drug Discovery at Griffith University, Queensland Australia.. Complete List of Published Work in My Bibliography.

Research Papers

Listed below are Prof David Finkelstein's most recent publications.

To improve loading times, 1/8 pages of publications are being displayed Click here to load all of this researcher's publications.


2017
2016
2015
2013


Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer's Disease.

Journal

J Alzheimers Dis

Volume

Not Found

Begin Page

Date

30/8/2017

Author(s)

Stuart D Portbury, Dominic J Hare, Charlotte Sgambelloni, Kali Perronnes, Ashley J Portbury, David I Finkelstein, Paul A Adlard
Trehalose improves traumatic brain injury-induced cognitive impairment

Journal

Plos One

Volume

12

Begin Page

Date

24/8/2017

Author(s)

Stuart D Portbury, Dominic J Hare, David I Finkelstein, Paul A Adlard
In vivo prion models and the disconnection between transmissibility and neurotoxicity

Journal

Ageing Research Reviews

Volume

36

Begin Page

156

Date

1/7/2017

Author(s)

Matteo Senesi, Victoria Lewis, Jee H Kim, Paul A Adlard, David I Finkelstein, Steven J Collins
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease

Journal

Acta Neuropathologica Communications

Volume

5

Begin Page

Date

28/6/2017

Author(s)

David I Finkelstein, Jessica L Billings, Paul A Adlard, Scott Ayton, Amelia Sedjahtera, Colin L Masters, Simon Wilkins, David M Shackleford, Susan A Charman, Wojciech Bal, Izabela A Zawisza, Ewa Kurowska, Andrew L Gundlach, Sheri Ma, Ashley I Bush, Dominic J Hare, Philip A Doble, Simon Crawford, Elisabeth CL Gautier, Jack Parsons, Penny Huggins, Kevin J Barnham, Robert A Cherny
Excessive early-life dietary exposure: a potential source of elevated brain iron and a risk factor for Parkinson's disease.

Journal

Npj Parkinsons Dis

Volume

3

Begin Page

1

Date

2017

Author(s)

Dominic J Hare, Bárbara Rita Cardoso, Erika P Raven, Kay L Double, David I Finkelstein, Ewa A Szymlek-Gay, Beverley-Ann Biggs
Age modulates the injury-induced metallomic profile in the brain

Journal

Metallomics

Volume

9

Begin Page

402

Date

1/4/2017

Author(s)

Stuart D Portbury, Dominic J Hare, Charlotte J Sgambelloni, David P Bishop, David I Finkelstein, Philip A Doble, Paul A Adlard
Pramipexole restores depressed transmission in the ventral hippocampus following MPTP-lesion

Journal

Scientific Reports

Volume

7

Begin Page

Date

14/3/2017

Author(s)

Javier Castro-Hernandez, Paul A Adlard, David I Finkelstein
Ferroptosis and cell death mechanisms in Parkinson's disease

Journal

Neurochemistry International

Volume

104

Begin Page

34

Date

1/3/2017

Author(s)

Stephanie J Guiney, Paul A Adlard, Ashley I Bush, David I Finkelstein, Scott Ayton

To improve loading times, 1/8 pages of publications are being displayed Click here to load all of this researcher's publications.